Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis

Carneiro, Sueli Coelho da Silva; Palominos, Penélope Esther; Anti, Sônia Maria Alvarenga; Assad, Rodrigo Luppino; Gonçalves, Rafaela Silva Guimarães; Chiereghin, Adriano; Lyrio, André Marun; Ximenes, Antônio Carlos; Saad, Carla Gonçalves Schahin; Gonçalves, Célio Roberto; Kohem, Charles Lubianca; Marques, Cláudia Diniz Lopes; Goldenstein-Schainberg, Cláudia; Meirelles, Eduardo de Souza; Resende, Gustavo Gomes; Pieruccetti, Lenise Brandao; Keiserman, Mauro Waldemar; Yazbek, Michel Alexandre; Sampaio-Barros, Percival Degrava; Lage, Ricardo da Cruz; Bonfiglioli, Rubens; Oliveira, Thauana Luiza de; Azevedo, Valderílio Feijó; Bianchi, W.; Bernardo, Wanderley Marques; Simões, Ricardo; Pinheiro, Marcelo de Medeiros; Campanholo, Cristiano

doi:10.1186/s42358-021-00219-y

Cited by 8 publications

(5 citation statements)

References 179 publications

(320 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, the findings corroborate the current clinical protocol and therapeutic guideline for psoriatic arthritis in the Unified Health System (2021) and the Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis, which recommend the use of any biological drug available or tofacitinib as options after failure with first line of biological drugs [42][43] .…”

Section: Discussionsupporting

confidence: 79%

Biological therapy in psoriatic arthritis patients with and without previous biologic experience

Silva

Santos

Kakehasi

et al. 2022

Medicina (Ribeirão Preto)

View full text Add to dashboard Cite

Objective: this study evaluated the biological therapy effects on disease activity, functionality, quality of life, drug survival, and safety of patients with psoriatic arthritis naïve and experienced in biological therapy. Methods: a oneyear prospective observational study was performed. The outcomes assessed were drug survival, disease activity, functionality, quality of life, and safety. Multiple linear regression was used to assess predictive factors for clinical response.Results: a total of 205 patients were included, 155 of whom were biologic naïve and 50 biologic experienced. Drug survival rate was greater for naïve patients than experienced patients at 6 months, but not at 12 months. Drug survival rates were 71.5% for naïve patients and 70.0% for experienced patients at 12 months. All clinical parameters improved for both biologic naïve and experienced patients. At 12 months, 63% of naïve patients and 52% of experienced patients had an improvement in their quality of life. Besides, 48% of naïve patients and 42% of experienced patients had an improvement in functionality. The axial disease improved in 67% of naïve individuals and 56% of experienced patients. Good control of peripheral disease was achieved by 49% of naïve patients and 44% of experiencedpatients. Female sex, use of etanercept or infliximab, and lower functionality or quality of life at baseline were the main predictors of poor clinical response. Conclusion: Patients’ health improved after starting biological therapy. In general, biologic experienced patients had more adverse reactions and lesser effectiveness.

show abstract

Section: Discussionsupporting

confidence: 79%

Biological therapy in psoriatic arthritis patients with and without previous biologic experience

Silva

Santos

Kakehasi

et al. 2022

Medicina (Ribeirão Preto)

View full text Add to dashboard Cite

show abstract

“…Recent studies have revealed that the CASPAR classification is more sensitive in terms of the diagnostic classification assessment of both early and late PsA disease compared to the ASAS criteria [ 45 ]. The Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis recommend clinical and imaging criteria for diagnosis and the CASPAR criteria for disease classification [ 46 ]. Still, it has limitations in cases of recent onset ( Table 3 ).…”

Section: Resultsmentioning

confidence: 99%

MRI Findings in Axial Psoriatic Spondylarthritis

et al. 2023

View full text Add to dashboard Cite

Psoriatic arthritis is a significant medical condition with a high prevalence, a wide variety of non-specific symptoms, and a high degree of overlap with other spondylarthritis disorders, particularly ankylosing spondylitis. Hence, knowledge of the magnetic resonance imaging (MRI) manifestations and a multidisciplinary strategy are required for the better management of these patients. We searched publications from the last 10 years and focused on the most relevant ones which discussed the classification criteria, the MRI characteristics of axial psoriatic arthritis, the importance of MRI for follow up, and the reliability of skin and synovial biopsy. Axial spondylarthritis can be diagnosed and followed up on using the well-established MRI technique and, additionally, a biopsy. The analysis and concordance between them can provide new directions for future studies.

show abstract

“…During the observation period of this study (i.e., 2017-2019), DAS28-CRP was still widely used to assess disease activity in PsA, in RCTs [18,22] as in daily practice [49]; one of the limits of this retrospective study is, in fact, the unavailability of the most recently validated outcome measures in PsA, such as the disease activity index for psoriatic arthritis (DAPSA) or the minimal and very low disease activity responses [50], as well as the lack of records relating to assessment tools for other clinical domains. On the other hand, DAS28-CRP has been shown to have a very high degree of correlation with DAPSA [49], and the use of DAS28-CRP in PsA patients has allowed us to draw a parallel with ASDAS-CRP in AS patients, thus comparing treatment outcomes both in terms of remission/inactive disease ± LDA achievement and according to ASAS/EULAR response criteria [21,22].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort

et al. 2023

View full text Add to dashboard Cite

Background Secukinumab has shown high efficacy in randomized controlled trials in both ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Here, we investigated its real-life effectiveness and tolerability in a cohort of AS and PsA patients. Methods We retrospectively analyzed medical records of outpatients with AS or PsA treated with secukinumab between December 2017 and December 2019. ASDAS-CRP and DAS28-CRP scores were used to measure axial and peripheral disease activity in AS and PsA, respectively. Data were collected at baseline and after 8, 24, and 52 weeks of treatment. Results Eighty-five adult patients with active disease (29 with AS and 56 with PsA; 23 males and 62 females) were treated. Overall, mean disease duration was 6.7 years and biologic-naïve patients were 85%. Significant reductions in ASDAS-CRP and DAS28-CRP were observed at all time-points. Body weight (in AS) and disease activity status at baseline (particularly in PsA) significantly affected disease activity changes. ASDAS-defined inactive disease and DAS28-defined remission were achieved in comparable proportions between AS and PsA patients, at both 24 weeks (45% and 46%) and 52 weeks (65.5% and 68%, respectively); male sex was found an independent predictor of positive response (OR 5.16, P = 0.027). After 52 weeks, achievement of at least low disease activity and drug retention were observed in 75% of patients. Secukinumab was well-tolerated and only mild injection-site reactions were recorded in 4 patients. Conclusion In a real-world setting, secukinumab confirmed great effectiveness and safety in both AS and PsA patients. The influence of gender on treatment response deserves further attention.

show abstract

Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis

Cited by 8 publications

References 179 publications

Biological therapy in psoriatic arthritis patients with and without previous biologic experience

Biological therapy in psoriatic arthritis patients with and without previous biologic experience

MRI Findings in Axial Psoriatic Spondylarthritis

Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort

Contact Info

Product

Resources

About